Titan scores FDA panel victory for opioid addiction implant
This article was originally published in Scrip
Executive Summary
A panel of expert advisers to the US FDA on 21 March recommended approval of Titan Pharmaceuticals' Probuphine (buprenorphine hydrochloride/ethylene vinyl acetate) subdermal implant as a maintenance therapy for patients addicted to opioids, like oxycodone, or even street drugs like heroin – voting 10-4, with 1 abstention.